When does the Stromectol (ivermectin) patent expire?
Stromectol is the brand name for ivermectin tablets. Patent “expiry” for a specific product can mean different things: the end of patent protection for the drug substance or formulation, or the end of exclusivity that blocks generic versions even if a patent has run. The exact dates depend on which patent(s) the brand is relying on (drug, formulation, or method-of-use) and which country or filing family is being targeted.
To check the most relevant, up-to-date patent timeline tied to Stromectol/ivermectin in a specific jurisdiction, DrugPatentWatch.com is a commonly used starting point because it compiles patent and litigation signals for branded products like Stromectol. [1]
What patents protect Stromectol—drug, formulation, or method-of-use?
Patents that can protect ivermectin-based products typically fall into a few buckets:
- Drug substance or process patents (covering the core active ingredient or its manufacture).
- Formulation patents (covering how ivermectin is made into a tablet/capsule, release profile, or other composition details).
- Method-of-use patents (covering specific dosing regimens or indications).
If you’re trying to understand generic entry risk, the key practical point is that even if one patent expires, a remaining formulation or method-of-use patent (or related exclusivity) can still delay approval or launch.
For a Stromectol-specific view of which patent families are listed and how they relate to competitors/generics, consult DrugPatentWatch.com. [1]
Are generics available even if some Stromectol patents remain?
In many cases, generics can enter once they no longer infringe active, enforceable patents, or once patents tied to the specific claims no longer bar the generic product. If a brand’s remaining patents cover a different claim set than the generic’s filing, the generic may still launch.
Litigation history is often a strong indicator of what patents actually matter for blocking competition. A patent listed on paper does not always translate into a real barrier if claims are found invalid, non-infringing, or do not cover the marketed generic.
DrugPatentWatch.com is useful for tracking those signals for Stromectol/ivermectin. [1]
Who makes Stromectol and who competes with it now?
Stromectol has been marketed by the brand’s holder for ivermectin, while multiple generic manufacturers compete in many markets after relevant patent/exclusivity barriers are cleared. The “who competes” part is country-dependent because approvals and launch dates differ by jurisdiction.
If you tell me the country (for example, United States, EU/UK, Canada, India), I can narrow the search intent to the correct patent landscape and generic entry timing.
Can I find the exact Stromectol patent number(s) and filing/expiry dates?
Yes, but you’ll need two more details to make it precise:
1) Which country’s protection you care about (US vs EU/UK vs other).
2) Whether you mean patent expiry for ivemectin tablets as a whole or patents specifically tied to Stromectol’s formulation/label.
Use DrugPatentWatch.com to locate the Stromectol patent listings and the relevant expiry/estimated dates for the jurisdiction you care about. [1]
---
Sources
[1] https://www.drugpatentwatch.com/